Literature DB >> 8045262

Overexpression of E2F-1 in rat embryo fibroblasts leads to neoplastic transformation.

P Singh1, S H Wong, W Hong.   

Abstract

The transcription factor E2F has been implicated in controlling the activation of multiple genes associated with cell proliferation. E2F-1, which is a component of E2F, can promote oncogenesis when transfected into REF cells. The transformation caused by E2F-1 correlates with constitutive overexpression of the transgene, increased transcription of E2F-dependent genes and the enhancement of two E2F DNA binding complexes containing the retinoblastoma susceptibility gene product (Rb) and E2F-1. The oncogenic potential of E2F-1 is dependent on functional DNA binding and transactivation domains but does not require the ability to interact directly with Rb. These findings provide the first direct evidence that sustained unregulated expression of E2F-1 can lead to the loss of cell proliferation control and that E2F-1 is a key component in cell cycle control.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8045262      PMCID: PMC395230          DOI: 10.1002/j.1460-2075.1994.tb06635.x

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  58 in total

1.  Molecular cloning of cellular genes encoding retinoblastoma-associated proteins: identification of a gene with properties of the transcription factor E2F.

Authors:  B Shan; X Zhu; P L Chen; T Durfee; Y Yang; D Sharp; W H Lee
Journal:  Mol Cell Biol       Date:  1992-12       Impact factor: 4.272

2.  Association of cdk2 kinase with the transcription factor E2F during S phase.

Authors:  M Pagano; G Draetta; P Jansen-Dürr
Journal:  Science       Date:  1992-02-28       Impact factor: 47.728

3.  Identification of a growth suppression domain within the retinoblastoma gene product.

Authors:  X Q Qin; T Chittenden; D M Livingston; W G Kaelin
Journal:  Genes Dev       Date:  1992-06       Impact factor: 11.361

4.  Human DNA polymerase alpha gene: sequences controlling expression in cycling and serum-stimulated cells.

Authors:  B E Pearson; H P Nasheuer; T S Wang
Journal:  Mol Cell Biol       Date:  1991-04       Impact factor: 4.272

5.  A cDNA encoding a pRB-binding protein with properties of the transcription factor E2F.

Authors:  K Helin; J A Lees; M Vidal; N Dyson; E Harlow; A Fattaey
Journal:  Cell       Date:  1992-07-24       Impact factor: 41.582

6.  The adenovirus E4 17-kilodalton protein complexes with the cellular transcription factor E2F, altering its DNA-binding properties and stimulating E1A-independent accumulation of E2 mRNA.

Authors:  M J Marton; S B Baim; D A Ornelles; T Shenk
Journal:  J Virol       Date:  1990-05       Impact factor: 5.103

7.  The retinoblastoma protein binds to a family of E2F transcription factors.

Authors:  J A Lees; M Saito; M Vidal; M Valentine; T Look; E Harlow; N Dyson; K Helin
Journal:  Mol Cell Biol       Date:  1993-12       Impact factor: 4.272

8.  Cloning and characterization of E2F-2, a novel protein with the biochemical properties of transcription factor E2F.

Authors:  M Ivey-Hoyle; R Conroy; H E Huber; P J Goodhart; A Oliff; D C Heimbrook
Journal:  Mol Cell Biol       Date:  1993-12       Impact factor: 4.272

9.  Inhibition of cell proliferation by p107, a relative of the retinoblastoma protein.

Authors:  L Zhu; S van den Heuvel; K Helin; A Fattaey; M Ewen; D Livingston; N Dyson; E Harlow
Journal:  Genes Dev       Date:  1993-07       Impact factor: 11.361

10.  Heterodimerization of the transcription factors E2F-1 and DP-1 leads to cooperative trans-activation.

Authors:  K Helin; C L Wu; A R Fattaey; J A Lees; B D Dynlacht; C Ngwu; E Harlow
Journal:  Genes Dev       Date:  1993-10       Impact factor: 11.361

View more
  50 in total

1.  Regulation of endogenous E2F1 stability by the retinoblastoma family proteins.

Authors:  F Martelli; D M Livingston
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

2.  Gene expression changes in response to E2F1 activation.

Authors:  Jens Stanelle; Thorsten Stiewe; Carmen C Theseling; Martin Peter; Brigitte M Pützer
Journal:  Nucleic Acids Res       Date:  2002-04-15       Impact factor: 16.971

3.  Use of chromatin immunoprecipitation to clone novel E2F target promoters.

Authors:  A S Weinmann; S M Bartley; T Zhang; M Q Zhang; P J Farnham
Journal:  Mol Cell Biol       Date:  2001-10       Impact factor: 4.272

4.  PPARgamma induces cell cycle withdrawal: inhibition of E2F/DP DNA-binding activity via down-regulation of PP2A.

Authors:  S Altiok; M Xu; B M Spiegelman
Journal:  Genes Dev       Date:  1997-08-01       Impact factor: 11.361

5.  RB and hbrm cooperate to repress the activation functions of E2F1.

Authors:  D Trouche; C Le Chalony; C Muchardt; M Yaniv; T Kouzarides
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-14       Impact factor: 11.205

6.  Adenoviral-E2F-1 radiosensitizes p53wild-type and p53null human prostate cancer cells.

Authors:  Khanh H Nguyen; Paul Hachem; Li-Yan Khor; Naji Salem; Kelly K Hunt; Peter R Calkins; Alan Pollack
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-09-01       Impact factor: 7.038

7.  Activation and association of Stat3 with Src in v-Src-transformed cell lines.

Authors:  X Cao; A Tay; G R Guy; Y H Tan
Journal:  Mol Cell Biol       Date:  1996-04       Impact factor: 4.272

8.  E2F1 has both oncogenic and tumor-suppressive properties in a transgenic model.

Authors:  A M Pierce; R Schneider-Broussard; I B Gimenez-Conti; J L Russell; C J Conti; D G Johnson
Journal:  Mol Cell Biol       Date:  1999-09       Impact factor: 4.272

9.  Second generation tyrosine kinase inhibitors prevent disease progression in high-risk (high CIP2A) chronic myeloid leukaemia patients.

Authors:  C M Lucas; R J Harris; A K Holcroft; L J Scott; N Carmell; E McDonald; F Polydoros; R E Clark
Journal:  Leukemia       Date:  2015-03-13       Impact factor: 11.528

10.  Functional interaction between DP-1 and p53.

Authors:  T S Sørensen; R Girling; C W Lee; J Gannon; L R Bandara; N B La Thangue
Journal:  Mol Cell Biol       Date:  1996-10       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.